Subscribe

News May 18, 2020 04:00 pm EqualOcean

The number of shareholders of Berry Genomics has declined for three consecutive periods

Analysis EO
Analysis · 2
report
Analysis EO
Sep 10, 2020 11:48 am ·

After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO

GRAIL, a US biotechnology company focused on early-stage pan-cancer screening, recently applied for an initial public offering (IPO) on Nasdaq. Backed up by the genetic-sequencing giant Illumina (ILMN:Nasdaq), the California-based company aims to find early-stage signs of cancer by examining a small amount of blood. The company raised a total fund of USD 1.69 billion in the previous four rounds, whose investors included Bill Gates and Bezos Expeditions. If the IPO goes smoothly, GRAIL will be the third Nasdaq-listed biotech company based on Next-Generation Sequencing (NGS) technology in the early-stage cancer detection area. Earlier in June, two Chinese companies, Burning Rock (BNR:Nasdaq) and Genetron Health (GTH:Nasdaq), went public on Nasdaq, raising the tide of genetic studies for cancer detection.  The demand for early-stage cancer screening is a universal one, with implications for all parts of a person's life cycle. In China, there is an enormous market potential, one expected to reach USD 170 billion in 2023. The top cancer types vary from country to country – the most damaging kinds in China are lung cancer and digestive systems cancers, while colorectal cancer wreaks havoc in the US. Pan-cancer studies tend to take a longer period to lead to technological breakthroughs. From a technology perspective, different players apply different methodologies. On a timeline logic, all trials can be divided into retrospective and prospective. For early-stage screening, the prospective trials take more time and costs and demand a higher precision requirement. In this money-losing competition, the tremendous future potential is the driver behind all the investments. A key takeaway at this moment is the need to deploy resources and build early business connections for the coming commercialization plans. When the technology is comparable, the marketing and selling area can be a critial success factor. In China's blue-ocean market, Genetron Holdings has already moved ahead, compared to Burning Rock. As indicated in the prospectus, the company has implemented several commercial moves, such as collaboration with hospitals, key opinion leaders (KOLs), commercial insurance service providers and medical examination centers (iKang Healthcare Group).  On top of the research cooperation and market expansion, the company has the ambition of building a to-C business model by co-developing customized insurance products and providing liver cancer early screening services via medical examination chain stops. As shown in the selling and marketing expense ratio, Genetron Holdings has been nibbling the market share of its competitors in China.  

News
News · 1
News
News · 1
News
Jun 8, 2020 06:46 pm · eastmoney

Buring Rock Will Land on Nasdaq this Friday

Announcements
Announcements · 1
Announcements
Feb 20, 2020 12:00 am · Berry Genomics

Complete 10,000 nucleic acid testing daily to help enterprises to resume production

Announcement: Click here
News
News · 1
News
News · 1
News
Feb 9, 2020 04:41 pm · Beijing Commercial Daily

Blocking new crown virus Berry Genomics launches next-generation sequencing kit

Announcements
Announcements · 1
News
News · 1
Briefing
Briefing · 1
Briefing
Updated 24 hours ago · Tencent Tech

JD Health’s New Move on Hong Kong IPO

Briefing
Briefing · 1
Briefing
Sep 18, 2020 10:58 am · VCbeat

Biotech IMAB’s In-Process New Drug Enters Clinical Trials

Briefing
Briefing · 1
Briefing
Sep 15, 2020 01:58 pm · VCbeat

3D Printing Precision Medicine Industry Park Lands in Hunan

Briefing
Briefing · 1
Briefing
Briefing · 1
Briefing
Briefing · 1
Briefing
Briefing · 1
Briefing
Sep 14, 2020 06:22 pm · VCbeat

Genor Biopharma Passes the Hearing for Hong Kong IPO

Briefing
Briefing · 1
Briefing
Briefing · 1
Briefing
Briefing · 1
Briefing
Sep 10, 2020 12:42 pm · VCbeat

WeMed Secures CNY 100 Mn in Series C+ from GL Ventures

Read more